Study of Maraviroc-Containing Regimens for HIV PrEP in U.S. Women: HPTN 069/ACTG A5305 Phase II Study
HPTN 069/ACTG A5305 is a Phase II study evaluating the safety and tolerability of Maraviroc (MVC)-containing regimens compared to Tenofovir/emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) in at-risk women. The study involves a randomized, double-blind, placebo-controlled design with
0 views • 18 slides
Enhancing Equitable Health Product Roll-out in Low- and Middle-Income Countries
Strategies to enhance equitable access to health products in low- and middle-income countries will be discussed at the AIDS 2022 conference, focusing on key factors such as availability, acceptability, affordability, accessibility, and quality. The Medicines Patent Pool aims to increase access to in
0 views • 14 slides
Impact of Antiretroviral Treatment on Weight and Obesity in HIV Patients
Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights
0 views • 31 slides
Comparing Adherence to HIV Pre-exposure Prophylaxis (PrEP) Among New Male PrEP Users Initiating F/TAF vs. F/TDF
This study aims to describe real-world use patterns and HIV seroconversion rates for individuals using emtricitabine/tenofovir disoproxil fumarate (F/TDF) vs. emtricitabine/tenofovir alafenamide (F/TAF) as pre-exposure prophylaxis (PrEP) for HIV prevention. The retrospective analysis includes newly
0 views • 9 slides